298 related articles for article (PubMed ID: 28215900)
21. Effectiveness of switching antipsychotic medications.
Essock SM; Covell NH; Davis SM; Stroup TS; Rosenheck RA; Lieberman JA
Am J Psychiatry; 2006 Dec; 163(12):2090-5. PubMed ID: 17151159
[TBL] [Abstract][Full Text] [Related]
22. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.
Katz I; de Deyn PP; Mintzer J; Greenspan A; Zhu Y; Brodaty H
Int J Geriatr Psychiatry; 2007 May; 22(5):475-84. PubMed ID: 17471598
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.
McEvoy JP; Lieberman JA; Stroup TS; Davis SM; Meltzer HY; Rosenheck RA; Swartz MS; Perkins DO; Keefe RS; Davis CE; Severe J; Hsiao JK;
Am J Psychiatry; 2006 Apr; 163(4):600-10. PubMed ID: 16585434
[TBL] [Abstract][Full Text] [Related]
24. Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials.
Stauffer V; Ascher-Svanum H; Liu L; Ball T; Conley R
BMC Psychiatry; 2009 Mar; 9():13. PubMed ID: 19335905
[TBL] [Abstract][Full Text] [Related]
25. Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia.
Deberdt WG; Dysken MW; Rappaport SA; Feldman PD; Young CA; Hay DP; Lehman DL; Dossenbach M; Degenhardt EK; Breier A
Am J Geriatr Psychiatry; 2005 Aug; 13(8):722-30. PubMed ID: 16085789
[TBL] [Abstract][Full Text] [Related]
26. Baseline Predictors of Antipsychotic Treatment Continuation and Response at Week 8 in Patients with Alzheimer's Disease with Psychosis or Aggressive Symptoms: An Analysis of the CATIE-AD Study.
Nagata T; Nakajima S; Shinagawa S; Plitman E; Nakayama K; Graff-Guerrero A; Mimura M
J Alzheimers Dis; 2017; 60(1):263-272. PubMed ID: 28800334
[TBL] [Abstract][Full Text] [Related]
27. Olanzapine versus other atypical antipsychotics for schizophrenia.
Komossa K; Rummel-Kluge C; Hunger H; Schmid F; Schwarz S; Duggan L; Kissling W; Leucht S
Cochrane Database Syst Rev; 2010 Mar; (3):CD006654. PubMed ID: 20238348
[TBL] [Abstract][Full Text] [Related]
28. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
29. Treatment changes among older patients with dementia treated with antipsychotics.
Kim HM; Chiang C; Weintraub D; Schneider LS; Kales H
Int J Geriatr Psychiatry; 2015 Dec; 30(12):1238-49. PubMed ID: 25759986
[TBL] [Abstract][Full Text] [Related]
30. Assessment of Reported Comparative Effectiveness and Safety of Atypical Antipsychotics in the Treatment of Behavioral and Psychological Symptoms of Dementia: A Network Meta-analysis.
Yunusa I; Alsumali A; Garba AE; Regestein QR; Eguale T
JAMA Netw Open; 2019 Mar; 2(3):e190828. PubMed ID: 30901041
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.
Volavka J; Czobor P; Citrome L; Van Dorn RA
CNS Spectr; 2014 Oct; 19(5):374-81. PubMed ID: 24284234
[TBL] [Abstract][Full Text] [Related]
32. Chlorpromazine versus atypical antipsychotic drugs for schizophrenia.
Saha KB; Bo L; Zhao S; Xia J; Sampson S; Zaman RU
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD010631. PubMed ID: 27045703
[TBL] [Abstract][Full Text] [Related]
33. Fluphenazine (oral) versus atypical antipsychotics for schizophrenia.
Sampford JR; Sampson S; Li BG; Zhao S; Xia J; Furtado VA
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD010832. PubMed ID: 27370402
[TBL] [Abstract][Full Text] [Related]
34. What CATIE found: results from the schizophrenia trial.
Swartz MS; Stroup TS; McEvoy JP; Davis SM; Rosenheck RA; Keefe RS; Hsiao JK; Lieberman JA
Psychiatr Serv; 2008 May; 59(5):500-6. PubMed ID: 18451005
[TBL] [Abstract][Full Text] [Related]
35. Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse.
Temmingh HS; Williams T; Siegfried N; Stein DJ
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD011057. PubMed ID: 29355909
[TBL] [Abstract][Full Text] [Related]
36. [Antipsychotics in bipolar disorders].
Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
[TBL] [Abstract][Full Text] [Related]
37. Comparison of risk of cerebrovascular events in an elderly VA population with dementia between antipsychotic and nonantipsychotic users.
Barnett MJ; Wehring H; Perry PJ
J Clin Psychopharmacol; 2007 Dec; 27(6):595-601. PubMed ID: 18004126
[TBL] [Abstract][Full Text] [Related]
38. Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.
Jin H; Shih PA; Golshan S; Mudaliar S; Henry R; Glorioso DK; Arndt S; Kraemer HC; Jeste DV
J Clin Psychiatry; 2013 Jan; 74(1):10-8. PubMed ID: 23218100
[TBL] [Abstract][Full Text] [Related]
39. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
[TBL] [Abstract][Full Text] [Related]
40. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.
Ballard C; Waite J
Cochrane Database Syst Rev; 2006 Jan; (1):CD003476. PubMed ID: 16437455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
